Use of bevacizumab as a single agent or in adjunct with traditional chemotherapy regimens in children with unresectable or progressive low‐grade glioma

MLA

Nataliya Zhukova, et al. “Use of Bevacizumab as a Single Agent or in Adjunct with Traditional Chemotherapy Regimens in Children with Unresectable or Progressive Low‐grade Glioma.” Cancer Medicine, vol. 8, no. 1, Dec. 2018, pp. 40–50. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....06f78148afc8e2301f5e1a097865d8af&authtype=sso&custid=ns315887.

APA

Nataliya Zhukova, Adrienne Lam, Thomas Walwyn, Kanika Bhatia, Lee Coleman, Jordan R. Hansford, Revathi Rajagopal, Molly Williams, Nicholas G. Gottardo, Martin Campbell, Michael J. Sullivan, & Peter Shipman. (2018). Use of bevacizumab as a single agent or in adjunct with traditional chemotherapy regimens in children with unresectable or progressive low‐grade glioma. Cancer Medicine, 8(1), 40–50.

Chicago

Nataliya Zhukova, Adrienne Lam, Thomas Walwyn, Kanika Bhatia, Lee Coleman, Jordan R. Hansford, Revathi Rajagopal, et al. 2018. “Use of Bevacizumab as a Single Agent or in Adjunct with Traditional Chemotherapy Regimens in Children with Unresectable or Progressive Low‐grade Glioma.” Cancer Medicine 8 (1): 40–50. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....06f78148afc8e2301f5e1a097865d8af&authtype=sso&custid=ns315887.